Abstract
Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.
| Original language | English |
|---|---|
| Pages (from-to) | 3159-3161 |
| Number of pages | 3 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 53 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 07-2009 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver